Balversa (Erdafitinib): Uses, Side Effects & Warnings

• Balversa (erdafitinib) is an oral kinase inhibitor approved for adults with locally advanced or metastatic urothelial carcinoma that has specific FGFR3 or FGFR2 genetic alterations.
• Patients must undergo genetic testing to confirm the presence of these alterations before starting treatment with Balversa.
• Common side effects include mouth sores, fatigue, changes in kidney function, and nail problems, while serious warnings involve ocular toxicity (eye problems) and hyperphosphatemia.
• Dosage is typically once daily, with adjustments made based on phosphate levels and individual tolerance.
• Close monitoring, particularly for eye health and blood phosphate levels, is essential throughout the treatment period.

What is Balversa (Erdafitinib)?

Balversa (erdafitinib) is an oral prescription medication classified as a fibroblast growth factor receptor (FGFR) kinase inhibitor. It is specifically designed to target and block the activity of FGFRs, which can be overactive in certain cancer cells and contribute to their growth and survival. By inhibiting these receptors, Balversa aims to slow or stop the progression of cancer.

This targeted therapy is distinct from traditional chemotherapy, as it focuses on specific molecular pathways implicated in cancer development, rather than broadly affecting rapidly dividing cells. The active pharmaceutical ingredient is erdafitinib, with Balversa being the brand name. Therefore, Balversa vs Erdafitinib information clarifies that they refer to the same drug, with erdafitinib being the generic name and Balversa the proprietary name under which it is marketed. This medication represents a significant advancement in personalized medicine for patients with specific genetic profiles.

For patients considering this treatment, understanding what is Balversa medication involves recognizing its role as a precision oncology drug. It is not a universal cancer treatment but rather a therapy tailored to individuals whose tumors exhibit particular genetic mutations. The U.S. Food and Drug Administration (FDA) granted accelerated approval for Balversa, highlighting its potential to address unmet medical needs in specific patient populations. This approval was based on tumor response rates and durability of response observed in clinical trials.

Balversa (Erdafitinib) Uses and Dosage

The primary Balversa uses and indications are for the treatment of adults with locally advanced or metastatic urothelial carcinoma (a type of bladder cancer) that has susceptible fibroblast growth factor receptor 3 (FGFR3) or FGFR2 genetic alterations. These alterations must be detected by an FDA-approved companion diagnostic test. Patients must also have progressed during or after at least one line of prior systemic therapy, or be ineligible for cisplatin-containing chemotherapy.

Before initiating treatment with Balversa, it is mandatory for patients to undergo genetic testing of their tumor tissue to confirm the presence of the specific FGFR alterations. This ensures that the medication is prescribed only to those who are most likely to benefit from its targeted mechanism of action. The efficacy and safety of Balversa have been evaluated in clinical studies, demonstrating its ability to induce objective responses in a subset of patients with these specific genetic markers.

Regarding Balversa dosage and administration, the recommended starting dose is typically 8 mg orally once daily. However, the dose may be increased to 9 mg once daily based on serum phosphate levels and tolerability after 14 to 21 days. It is crucial to take Balversa at approximately the same time each day, with or without food. Patients should swallow the tablets whole and not crush, chew, or split them. Dose adjustments or interruptions may be necessary based on the occurrence and severity of adverse reactions, as well as changes in serum phosphate levels. Close monitoring by a healthcare professional is essential to manage the treatment effectively and safely.

Potential Side Effects and Warnings of Erdafitinib

Like all medications, Balversa (erdafitinib) can cause side effects, some of which can be serious. Patients receiving Erdafitinib patient information should be fully aware of these potential adverse reactions and how to monitor for them. The most common side effects reported in clinical trials include:

• Stomatitis (mouth sores)
• Fatigue
• Diarrhea or constipation
• Nail changes (e.g., brittle nails, nail detachment)
• Alopecia (hair loss)
• Dry mouth, dry skin
• Changes in kidney function (increased creatinine)
• Increased phosphate levels in the blood (hyperphosphatemia)
• Eye problems (e.g., dry eyes, blurred vision)

The Erdafitinib side effects list also includes more serious concerns. One of the most significant Balversa drug warnings is ocular toxicity, specifically retinal detachment and central serous retinopathy. These conditions can lead to visual impairment, and in some cases, permanent vision loss. Patients should undergo a comprehensive eye examination, including optical coherence tomography (OCT), before starting treatment and periodically during treatment, as recommended by their doctor. Any changes in vision, such as blurred vision, halos around lights, or difficulty seeing in low light, should be reported immediately to a healthcare provider.

Another important warning is hyperphosphatemia, an increase in phosphate levels in the blood, which is a pharmacodynamic effect of FGFR inhibition. Serum phosphate levels should be monitored regularly, typically weekly for the first month, and then monthly or as clinically indicated. If phosphate levels become too high, dose adjustments or temporary interruption of treatment may be necessary. Balversa can also cause embryo-fetal toxicity, meaning it can harm an unborn baby. Women of reproductive potential should use effective contraception during treatment and for one month after the last dose, and men with female partners of reproductive potential should use effective contraception during treatment and for one month after the last dose. Patients should discuss all potential risks and benefits with their healthcare team before starting Balversa.

Frequently Asked Questions About Balversa (Erdafitinib)

What kind of cancer does Balversa treat?

Balversa (erdafitinib) is specifically approved to treat adults with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. This treatment is only effective for patients whose tumors have specific genetic alterations in the FGFR3 or FGFR2 genes, which must be identified through an FDA-approved diagnostic test. It is typically used after other systemic therapies have been tried or if a patient is not eligible for certain chemotherapies, offering a targeted approach to managing this aggressive cancer.

How is Balversa administered?

Balversa is an oral medication taken as tablets once daily. It can be taken with or without food, but it is important to take it at approximately the same time each day to maintain consistent drug levels in the body. Patients should swallow the tablets whole and avoid crushing, chewing, or splitting them. The dosage may be adjusted by a healthcare provider based on the patient’s individual response, phosphate levels, and any side effects experienced during treatment.

What are the most important side effects to watch for with Balversa?

The most critical side effects to monitor while taking Balversa are eye problems (ocular toxicity) and elevated phosphate levels in the blood (hyperphosphatemia). Ocular toxicity can manifest as blurred vision, dry eyes, or more serious conditions like retinal detachment, potentially leading to vision loss. Regular eye exams are crucial. Hyperphosphatemia requires consistent blood monitoring, as high phosphate levels can lead to complications. Patients should report any visual changes or unusual symptoms to their doctor immediately.